A remarkable case report has drawn attention after an elderly woman with advanced Alzheimer’s disease appeared to show unexpected improvements following supervised treatment with psilocybin mushrooms. The woman, a Japanese American in her 80s, had experienced progressive cognitive decline for around ten years. During the previous five years, she was largely limited to speaking single words, relied on others for everyday activities, had difficulty walking and dressing herself, and experienced persistent urinary incontinence. Under professional supervision, she received a 5-gram dose of psilocybin-containing mushrooms. Within approximately 19 hours, her caregivers noticed significant changes. They reported that she began speaking in full sentences, reminiscing about past experiences, and interacting more with those around her. Over the following days and weeks, she became more engaged, recognized family members, walked with greater independence, dressed herself, and even regained bladder control. A month later, she underwent a second supervised session using a 3-gram dose. Caregivers again observed improvements in her speech, mobility, and overall responsiveness. Although these observations are striking, they should not be interpreted as evidence that psilocybin can cure or reverse Alzheimer’s disease. This describes only a single patient rather than a controlled clinical study. Her Alzheimer’s diagnosis was made from her medical history and clinical assessment, without confirmation using brain imaging or biomarker testing such as spinal fluid analysis. The report also lacked standardized cognitive assessments before and after treatment, a comparison group, and any evidence that the underlying brain changes associated with Alzheimer’s had been repaired. Even so, the case has generated scientific interest. Psilocybin primarily acts on serotonin receptors in the brain and has demonstrated effects in laboratory and animal research on neuroplasticity, communication between brain networks, inflammation, and the formation of new connections between nerve cells. Some scientists speculate that these changes might briefly improve the efficiency of remaining healthy brain circuits, allowing abilities that had become difficult to express to emerge more clearly. However, this idea remains a hypothesis and has not yet been confirmed in people with Alzheimer’s disease. It’s also important to remember that psilocybin is not without risks, particularly for older adults or those with significant medical conditions. In this case, the woman reportedly experienced excessive sweating, a possible fever, and an unusually prolonged sleep-like period after treatment.